Nampt-IN-18
Nampt-IN-18 (Compound Q24) is an orally active NAMPT inhibitor with an IC50 of 8.0 nM against hNAMPT. Nampt-IN-18 inhibits NAMPT enzymatic activity. Nampt-IN-18 inhibits DNA synthesis and induces Apoptosis. Nampt-IN-18 exhibits anticancer activity against gastric cancer and colorectal cancer. Nampt-IN-18 can be used for the research of gastrointestinal cancers.
For research use only. We do not sell to patients.
- Formula: C27H30FN5O2
- Molecular Weight:475.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
IC50: 8.0 nM against hNAMPT[1]
In Vitro
Nampt-IN-18 (30 min) potently inhibits the enzymatic activity of recombinant hNAMPT, with an IC50 of 8.0 ± 1.9 nM[1].
Nampt-IN-18 (72 h) potently inhibits the viability of HGC-27 gastric cancer cells, with an IC50 of 0.69 ± 0.14 nM[1].
Nampt-IN-18 (72 h) inhibits the viability of LOVO colon cancer cells with an IC50 of 63 ± 12 nM[1].
Nampt-IN-18 (72 h) inhibits the viability of Caco-2 colorectal adenocarcinoma cells, with an IC50 of 6.5 ± 2.2 nM[1].
Nampt-IN-18 (0.25-1 nM; 24 h) inhibits DNA synthesis in HGC-27 gastric cancer cells in a dose-dependent manner, with a strong inhibitory effect observed at 1 nM[1].
Nampt-IN-18 (1-4 nM; 48 h) induces significant G1-phase and G2/M-phase cell cycle arrest in HGC-27 gastric cancer cells[1].
Nampt-IN-18 (1-4 nM; 48 h) induces apoptosis in HGC-27 gastric cancer cells in a dose-dependent manner[1].
Nampt-IN-18 (0.25-1 nM; 24 h) inhibits the migration of HGC-27 gastric cancer cells in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human gastric cancer HGC-27 cells
-
Concentration:1-4 nM
-
Incubation Time:48 h
-
Result:Induced measurable apoptosis (~5-11% apoptotic cells) at 1-2 nM.
Induced ~53% apoptotic cells at 4 nM.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | MRT0-∞ | CL |
|---|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.g. | 1.86 h | 0.67 h | 67.43 μg/L | 2.51 h | 68.63 L/h/kg |
In Vivo
Nampt-IN-18 (300 mg/kg; i.g.; single dose) is well tolerated in healthy KM mice, with no acute toxicity or organ damage observed[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:3.75 mg/kg; 7.5 mg/kg; 15 mg/kg
-
Administration:i.g.; bid; 12 consecutive days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 68.9% at 15 mg/kg dose.
Caused no significant body weight loss across all tested doses (15 mg/kg caused transient early weight loss with subsequent recovery to levels not significantly different from the vehicle group).
Reduced terminal tumor weights significantly at all tested doses compared to the vehicle group.
Detected no histopathological abnormalities in the heart, liver, spleen, lung, or kidney at any tested dose.
Chemical Information
-
Molecular Weight 475.56
-
Formula C27H30FN5O2
-
SMILES
O=C(NC1=CC=C([C@H](C)NC(C2=C(N3CCCCC3)C=CC(F)=C2)=O)C=C1)NCC4=CC=CN=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)